Xalud Therapeutics shifts focus to gene therapies for ALS treatment.
TL;DR Summary
Xalud Therapeutics has shifted its focus to gene therapy, elevating a preclinical ALS program and putting its lead non-viral gene therapy on the partnering path, while letting go of employees, according to a former employee.
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
61%
90 → 35 words
Want the full story? Read the original article
Read on Endpoints News